Director Daniel Swisher Jr. filed a Form 144 notice of proposed sale of 1,500 shares of Corcept Therapeutics Incorporated common stock, dated November 10, 2026, pursuant to Rule 144 under the Securities Act of 1933.

Key Highlights

  • Seller: Daniel Swisher Jr., identified in the filing as a Director of Corcept Therapeutics Incorporated.
  • Shares proposed for sale: 1,500 shares of common stock, with an aggregate market value of $112,537.50 as stated in the filing.
  • Acquisition method: The 1,500 shares were acquired on November 10, 2026, through exercise of stock options from the issuer, with cash payment on the same date.
  • Shares outstanding: According to the filing, 109,443,109 shares of common stock were outstanding at the time of notice.
  • Exchange and broker: The proposed sale is to be executed on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, 8th Floor, New York, NY 10004.
  • Rule 10b5-1 plan: The filing indicates a trading plan adoption date of August 3, 2026.
  • Prior three-month sales: The filing reports nothing to report for securities sold during the past three months.

Corcept Therapeutics Director Swisher Proposes Option-Exercised Share Sale on NASDAQ

According to the Form 144 notice filed with the U.S. Securities and Exchange Commission, Daniel Swisher Jr., a Director of Corcept Therapeutics Incorporated (NASDAQ:CORT), disclosed a proposed sale of 1,500 shares of the company's common stock. The notice is dated November 10, 2026, and lists an aggregate market value of $112,537.50 for the shares to be sold. The approximate date of sale indicated in the filing is November 10, 2026.

The filing states that the 1,500 shares were acquired on November 10, 2026, through the exercise of stock options granted by the issuer, with payment made in cash on the same date. No prior sales of the issuer's securities were reported by Swisher in the past three months, as the filing notes "Nothing to Report" for that section. The filing further discloses that the proposed transaction is associated with a written trading plan adopted on August 3, 2026, in reliance on Rule 10b5-1 under the Exchange Act.

The filing identifies Corcept Therapeutics Incorporated as the issuer, with its principal address at 101 Redwood Shores Parkway, Redwood City, California 94065. The SEC file number listed is 000-50679. The total shares of common stock outstanding at the time of the notice were reported as 109,443,109.

What Was Disclosed

Director Daniel Swisher Jr. filed a Form 144 notice proposing to sell 1,500 Corcept Therapeutics common shares, acquired via stock option exercise on November 10, 2026, with an aggregate market value of $112,537.50, under a Rule 10b5-1 plan adopted August 3, 2026.